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Neonatal abstinence syndrome (NAS) is seen at a very high rate at our institution in Huntington, 
West Virginia, and the majority of exposures are polysubstance in nature. Polysubstance can 
have different meanings for different regions. At our institution, polysubstance is any 
combination of opioids, gabapentin, methamphetamine, cocaine, marijuana, benzodiazepines, 
nicotine or other neuroactive substances with three to four substances being the norm. Rapidly 
changing combinations of drug use and the lack of literature creates a difficult situation for 
clinicians who are often reliant on treatment recommendations that lack references or conclusive 
data supporting the clinical approaches. Elucidating withdrawal symptoms consistent with in 
utero exposures to particular drug combinations is difficult. Many substances induce similar 
withdrawal symptoms in neonates and the vast majority of cases present as polysubstance 
exposure. Standard methodology often leads to a research approach which isolates populations 
and substance of exposure to determine the individual effects on the neonate. In some drug 
combinations, like opioid and gabapentin exposure, the substances in concert create symptoms 
and complications that are not observed with either drug alone. The history of responses to 
substance use epidemics has been to handle each drug as a separate disease process; this is no 
longer a viable option.  The following is a review of the literature available discussing individual 
substance withdrawal characteristics in neonates combined with the clinical insight gained at our 








Our institution in Huntington, West Virginia is at the center of the opioid epidemic, and because 
of this, we see many cases of neonatal abstinence syndrome (NAS). Despite our institution’s 
experience treating NAS, it is important to note the limitations and complications of treatment 
and research. The lack of literature and studies involving substance abuse outcomes for neonates 
is crippling. Kraft and van den Anker describe a deficit of reliable data to assist practitioners in 
determining the best NAS treatment and gaps in knowledge become more prominent when 
discussing polysubstance abuse.1 Furthermore, polysubstance abuse in the literature is described 
more as co-substance abuse. For example, opioid and gabapentin or opioid and nicotine are both 
described as polysubstance abuse. The polysubstance abuse our institution and many others face 
is a result of mixing opioids, gabapentin, methamphetamine, cocaine, marijuana, nicotine, as 
well as fads and designer cocktails that are seen from time to time. As a result, practitioners are 
reliant upon clinical findings, limited case studies, and off-label use in an attempt to manage 
withdrawal symptoms in complicated severe NAS cases.  
 
According to Carrasco, Rao, Bearer and Sundararajan, readily established protocols are available 
for the treatment of NAS.2 While the framework from treatment remains largely consistent as 
described by Kraft and van den Anker, the details of treatment can differ greatly, potentially 
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contributing to infant outcomes.1 These protocols are based upon knowing the substance of 
exposure and largely are not adapted to include polysubstance exposure. Identifying and 
confirming the substance used during pregnancy is often times frustrating and a complication to 
treatment. According to Behnke and Smith there are two main methods of identifying substances 
used during pregnancy: self-report and biological specimens.3 No single approach can accurately 
determine the presence, dosage, or duration of substances used during pregnancy and each 
method both for biological samples and self-report has strengths and weaknesses. Urine drug 
screens (UDS), umbilical cord toxicology, and self-report are the most common methods of 
substance abuse detection. Confirming the exact exposures, therefore, is often limited to what 
happens close to time of delivery and is also limited by what the biological test itself is designed 
to detect.   
 
A third notable limitation is the ever-changing trends in common combinations of drug abuse. 
Pregnant women use a wide variety of substances with common patterns of polysubstance abuse 
with polysubstance use as high as 50% in some studies.4 The common combinations have been 
known to follow trends in substance abuse including substances that are popular or readily 
available at the time. The problem in identifying trends in substance abuse is the high turn-over 
of popular trends. Due to the ever-changing substance abuse environment, it is impossible to 
predict the next trend, common combinations of substances, or which substance will be the next 
epidemic.  
 
Although not all substances used during pregnancy will induce a withdrawal syndrome in the 
neonate, post-delivery symptomatic evidence of exposure for each of most commonly used 
substances during pregnancy exists.  When used in differing combinations, unique symptoms are 
present in the neonate indicating which substances may have been combined during pregnancy. 
While confirming exposure would still be limited, symptoms can provide more information 
creating a more complete picture. By identifying how substances and differing combinations 
change the neonatal symptoms, it could be possible to eliminate some of the limiting factors of 
NAS treatment. The unique symptomology could provide a roadmap to treatment helping 
practitioners make more informed treatment decisions resulting in more appropriate, timely 
treatment and possibly improved neonatal outcomes.  
 
The following aims to combine our clinical observations with information from the literature to 
create a document for recognizing NAS and inform treatment decisions. Included in this 
document are reviews of symptomology and outcomes according to substance exposure, 
pharmacological treatment of NAS, and descriptions of common combinations of drugs seen in 
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Proposed Treatment  
Opioid and 
Gabapentin 
27.7% Stepwise weaning with accepted opioid 
alternative. If the neonate does not respond, 
stepwise weaning with gabapentin may be 
required. 
Opioid and THC 29.4% Stepwise weaning with accepted opioid 
alternative. Clonidine as adjunctive agent in 
severe withdrawal cases.  
Opioid and 
Benzodiazepine 
13% Stepwise weaning with accepted opioid 
alternative. Clonidine or a matched 
benzodiazepine as adjunctive agent in 
severe withdrawal cases. 
Opioid and Stimulant  14.7% Stepwise weaning with accepted opioid 
alternative. Clonidine as adjunctive agent in 
severe withdrawal cases. 
Opioid and 
Nicotine/Caffeine 
88% Stepwise weaning with accepted opioid 
alternative. Clonidine as adjunctive agent in 
severe withdrawal cases. 
 
Scope and Purpose 
 
A literature search of published research related to neonatal abstinence syndrome and 
polysubstance exposure was combined with clinical experience from a hospital with a dedicated 
NAS unit that treats 200-300 neonates annually with proven prenatal exposure and severe 
withdrawal symptoms to produce this manuscript.5   
 
The goal was to combine what was published in literature with what our hospital sees on a day-
to-day basis in hopes of presenting a guide for each presentation of neonatal abstinence 
syndrome due to polysubstance exposure. The literature search was not limited based on date or 
study design. We did not look at alcohol exposure for this review due to low reliability in testing. 
 
Common Combinations of Substance Abuse 
 
In the discussion of the withdrawal symptoms consistent with particular in utero exposures it is 
important to consider the difficulty of these evaluations. Not only do many substances induce 
similar withdrawal symptoms in neonates, but in many populations, including that at our 
institution, the vast majority of neonates with NAS present with polysubstance exposure. This 
reality may change the withdrawal symptoms altogether.  Therefore, we consider the symptoms 
that are indicative of certain drug exposures that are seen in cases of neonates exposed to the 
substance alone (Table 2) and those accompanied by other substances.  
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Table 2. In utero substance exposure and characteristic withdrawal symptoms 
 







Fever, sweating, tremors, 
irritability, excessive crying, 
hypertonic, hyperactive Moro 
reflex, myoclonic jerks, skin 
mottling, sleep disturbance, 
vomiting, sneezing, abdominal 
cramping/gas, excoriation, 
yawning, diarrhea (loose/liquid 
stools), tachypnea, poor feeding, 
excessive/disorganized suck 
Low birth weight, IUGR, 
prematurity, preeclampsia, 
small head circumference, 
impaired learning and 
memory 
 
Reduced cognitive function 
and school performance 
 
Motor delays 
(11, 24)  
Marijuana 
Irritability, hyperactive Moro 
reflex, excessive suck, increased 
startles and tremors 
Low birth weight, shorter 
gestation, prolonged sleep 
disturbances 
 
Visual development issues, 





Delayed symptom onset, fever, 
tremors, irritability, sleep 
disturbance, vomiting, diarrhea, 
sneezing, muscle twitching, 
yawning, excessive crying, 
grimacing, jitteriness, seizures 





Delayed symptom onset, 
Irritability, hypertonia, diarrhea, 
vomiting, feeding difficulty, 
vasomotor instability 




Fever, tremors, excoriation, 
vomiting, loose stools, sneezing 
Low birth weight, 
premature birth 
 
Long-term adverse effects 
on behavior, cognitive 
skills, and physical dexterity 
(18) 
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Fever, tremors, irritability, sleep 
disturbance, vomiting, diarrhea, 
sneezing, feeding difficulty, 
failure to thrive, jitteriness, 
excessive suck, hyperactive 
Moro reflex 
Poor fetal growth, 
prolonged growth 
restriction, developmental 




Back arching, continuous 
extremity movement, tongue 
thrusting, wandering eye 
movements, increased muscle 
tone 
Preterm birth, low birth 
weight  
(8) (2) (8) 
SSRI’s 
Irritability, seizure, agitation, 
tremors, hypertonia, increased 
respiratory rate, nasal 
congestion, emesis, diarrhea, 
feeding difficulty, fever, 
hypoglycemia 
Effects on motor 




Greater need for handling, poor 
self-regulation, irritability, 
hypertonia 










1. Common Combinations of Substance Abuse 
 
The following will outline the common combinations of substance abuse attributing to NAS as 
seen in a high volume specialized unit in Huntington, West Virginia. Literature descriptions of 
each combination will be included when available however, due to the volume of polysubstance 
related NAS cases seen in our hospital, the focus of this section is to give a brief outline of our 
own observations in hopes of providing a guide to distinguish the different types of 
polysubstance induced NAS.  
 
1.1 Opioid/Gabapentin Withdrawal 
 
Several studies have been published analyzing the abuse of opioids in combination with 
gabapentin, which is traditionally used to treat partial seizures, neuropathic pain, and restless leg 
syndrome. Baird, Fox and Colvin6 found that 22% of their 129 surveyed respondents abused 
gabapentin in conjunction with methadone, with 38% of those respondents citing gabapentin’s 
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ability to potentiate the effects of methadone as their reason for the concurrent drug use. An 
additional study from Bastiaens, Galus, and Mazur7 found that 26% of their 250 surveyed 
respondents admitted to illegally obtaining or abusing gabapentin. Despite being currently 
deemed safe for prescription used during pregnancy, in utero gabapentin exposure has been 
associated with risk for preterm birth and low birth weight.8 Although opioid/gabapentin NAS 
has not been widely explored, there have been reports of withdrawal syndromes in neonates 
exposed to gabapentin alone, in which symptoms of poor feeding, poor coordination, sneezing, 
irritability, jitteriness, and loose stools were observed.2  
 
Neonates presenting with withdrawal secondary to in utero exposure to both opioids and 
gabapentin has grown over the last few years at our institution, although prevalence is difficult to 
describe due to our previous primary reliance on maternal admission of drugs abused. Symptom-
based diagnoses have increased as the hallmark symptoms of opioid/gabapentin withdrawal have 
become better described. The symptoms associated with opioid/gabapentin neonatal withdrawal 
in a cohort at our institution were described by Loudin et al.9 The symptoms included increased 
neurobehavioral issues such as tongue thrusting, nystagmus, excessive arching of the back, and 
exaggerated myoclonic jerks of the extremities. These symptoms prohibit typical weaning of the 
neonate from the opioids, and in the study on opioid/gabapentin withdrawal, 10 of the 19 
neonates described by Loudin et al. required additional pharmacologic therapy in order to wean.9 
These 19 neonates included in this study comprised 10% of the neonates treated for NAS in our 
hospital for that year.  
 
Our institution has developed a protocol for opioid/gabapentin withdrawal which involves a step-
wise weaning of the neonate. This treatment protocol begins with the standard treatment of NAS 
using an accepted opioid alternative.  If the neonate does not respond to this, gabapentin may be 
required as well, stepping down dosage of gabapentin every three days until symptoms subside.9 
The average length of treatment for neonates treated throughout the combined weaning therapy 
in that early study was 47 +/- 8.8 days.9 The long-term effects of opioid/gabapentin withdrawal 
are not well known, and is an area for further study.  
 
In response to the growing incidence of NAS associated with opioid/gabapentin exposure, we 
have recently adopted a new urine drug screen (UDS) that is capable of detecting gabapentin use. 
This new UDS provides physicians with the advantage of supplemental information regarding 
potential exposures in addition to maternal confession. However, this adaptation also highlights 
the importance of recognizing specific symptoms in neonates. Before the addition of a new UDS 
physicians had to rely on maternal admission and neonatal symptoms to determine the likely 
exposure and to decide on appropriate treatment for the neonate. As trends in substance abuse 
change it is likely that UDS readily available may not screen for popular substances of abuse and 
that physicians will rely more heavily on symptom base diagnosis.  
 
1.2 Opioid/THC Withdrawal 
 
The use of marijuana during pregnancy amongst women seeking substance abuse treatment at 
federally funded treatment centers is on the rise, at 43% nationally.10 Even outside the population 
of individuals with substance abuse disorders, marijuana is the most commonly used illicit drug 
during pregnancy,4 and is considered to be safe among users and a subset health care 
44
Marshall Journal of Medicine, Vol. 5 [2019], Iss. 2, Art. 9
https://mds.marshall.edu/mjm/vol5/iss2/9
DOI: 10.33470/2379-9536.1212
professionals. Conversely, in utero marijuana exposure is thought to cause long-term 
complications, although it is difficult to flawlessly describe as it is often used in conjunction with 
other illicit substances. Furthermore, the existing studies focused on marijuana use in isolation 
during pregnancy are conflicting. Some studies report significant long-term effects, some report 
subtle effects while others report no lasting long-term effects making it difficult to discern the 
neonatal outcomes.  Similarly, the studies that exist for short-term outcomes are also conflicting. 
 
In our hospital, we see marijuana exposure in many of our complex polysubstance presentations 
of NAS. Statistics from our institution from 2013-2015 data show that amongst our positive 
umbilical cord blood toxicology tests from neonates presenting with NAS, roughly 36% 
(431/1212) test positive for cannabinoids. When analyzed for combination of substances, opioids 
and cannabinoids are used concurrently in 16% (198/1212) of cases. The symptoms that have 
been reported in the literature associated with in utero marijuana exposure include increased 
irritability, tremors, hyperactivity Moro reflex, excessive suck and increased startles.11,12 These 
symptoms are often accompanied by decreased birth weight, shorter gestation, and sleep 
disturbances.12  While these symptoms are similar to that of opioid withdrawal, and often 
difficult to differentiate, a true withdrawal syndrome secondary to marijuana exposure has not 
been described in the literature.13 Furthermore, while symptoms exist in the neonate no reports of 
treatment used to manage the symptoms have been reported in the literature.   
 
The use of marijuana with opioids seems to lead to a more severe withdrawal profile as noted 
within our patient population. This may indicate the need to resort to self-report or a different 
biological specimen to confirm exposure.  Treatment for the cases with confirmed marijuana 
exposure at our institution is often dependent on the treatment of the opioid withdrawal, 
involving a step-wise weaning of the neonate using an acceptable opioid alternative with the 
addition of clonidine as an adjunctive agent in the more severe cases. Worsening severity is of 
concern for infants exposed to marijuana in utero as the concentration of THC (∆-9-
Tetrahydrocannabinol) has gradually increased since selective cultivation.12 Due to the wide use 
of marijuana, increasing THC concentrations, and the conflicting literature further research in the 
neonatal outcomes is warranted.  
 
1.3 Opioid/Benzodiazepine Withdrawal 
 
Co-abuse of opioids and benzodiazepines occurs frequently in our hospital.  Corroborating 
statistics from 2013-2015 show that amongst our positive umbilical toxicology tests from 
neonates presenting with NAS, roughly 29% (346/1212) test positive for benzodiazepines and 
roughly 16% (199/1212) test positive for benzodiazepines in combination with opioids.  
 
In a study analyzing the withdrawal effects of selective serotonin reuptake inhibitors (SSRI) both 
with and without concomitant benzodiazepines, Salisbury et al14 found that benzodiazepines tend 
to worsen the withdrawal symptoms in the neonate. The symptoms mentioned in that study 
include low mobility of the neonate, high levels of CNS stress, and decreased arousal. 
Swortfiguer et al reported that in maternal benzodiazepine use in the last month of pregnancy 
resulted in symptoms of hypotonia and hypoventilation in 42% of the reviewed cases.15  
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At our institution, we have observed that neonates with NAS associated with in utero exposure to 
benzodiazepines exhibit a delayed onset, in which symptoms present two to three weeks after 
birth. This may present as a “set-back” for a neonate who had previously been weaning steadily. 
Characteristic withdrawal symptoms include fever, tremors, irritability, sleep disturbance, 
vomiting, diarrhea, sneezing, muscle twitching, yawning, excessive crying, grimacing, 
jitteriness, and seizures. In addition, these neonates often display a unique oral aversion. While 
the symptoms have been displayed frequently at our institution in infants exposed to both opioids 
and benzodiazepines, support by the literature is limited as polysubstance studies are infrequent 
or limited to exposures. Treatment for this particular combination of drugs involves the step-wise 
weaning of the neonate with an acceptable opioid alternative, with the addition of clonidine 
and/or a matched benzodiazepine if needed to control the withdrawal symptoms.  
 
1.4 Opioid/Stimulant Withdrawal 
 
Cocaine withdrawal in the neonate is well described, owing to the prevalence of cocaine abuse in 
the 1980s and the subsequent response by researchers to understand the implications of abuse. In 
utero stimulant exposure may lead to low birth weight and premature birth.11 On its own, cocaine 
acts as a vasoconstrictor to decrease blood flow in utero while blocking the reuptake of 
dopamine and other neurotransmitters during development, producing defects in CNS 
formation.16 Intrauterine cocaine exposure has been shown to epigenetically decrease the 
expression of 11B-HSD-2, which normally changes cortisol to cortisone in an effort to decrease 
glucocorticoid exposures in the fetus.16  
 
In our experience, neonatal withdrawal from the combination of opioid and cocaine in utero 
exposure can produce more irritable neonates with tremors and a high-pitched cry. In addition, 
symptoms characteristic of this exposure combination includes failure to thrive further 
complicated by fever, sleep disturbance, diarrhea, sneezing, difficulty feeding, jitteriness, 
excessive suck and hyperactive Moro reflex. Treatment for these neonates involves stepwise 
weaning of the neonate from the opioids with an acceptable opioid alternative with the addition 
of clonidine to help control withdrawal symptoms in the more severe cases.  
 
In addition to concerns regarding cocaine use, methamphetamine use has grown world-wide, 
with Terplan et al17 reporting that 24% of pregnant women in federally funded treatment centers 
in the United States admitted to using methamphetamines during pregnancy. We have observed 
at our institution that opioid/methamphetamine withdrawal is increasingly common among 
neonates with NAS, and its treatment mirrors the treatment for opioid/cocaine withdrawal. The 
neonates with in utero methamphetamine withdrawal typically exhibit fever, tremors, 
excoriation, vomiting, loose stools, and sneezing.  
 
While the use of methamphetamine increasing, including the use in pregnant women or in 
women of child bearing age, little is known about the neonatal outcomes both short and long-
term. Some studies report neonatal neurobehavioral patterns of decreased arousal, increased 
stress, poor movement quality, and increased incidence of small for gestational age and 
prematurity associated with in utero exposure to methamphetamine.18 The exposure has also 
been associated with a high incidence of being admitted to the newborn intensive care unit and 
more likely to exhibit poor suck and have small head circumference at birth.18 Other studies 
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regarding methamphetamine exposure have focused on issues of the social, economic, and 
psychological disadvantages that accompany the illicit drug use. One such study reports that 
pregnant substance users face elevated risks that subsequently affect child development.17 While 
vastly important details confound many of the research studies, these findings and the lack of 
literature warrant further research.  
 
1.5 Withdrawal Combined with Nicotine/Caffeine 
 
While not an illegal substance, tobacco use during pregnancy occurs at a high frequency, 
especially amongst pregnant women using opiates. Forray et al19 reported that 77% of women in 
their study with concurrent substance abuse smoked cigarettes and throughout their pregnancy 
only 29% of those women achieved abstinence. Therefore, it is important to report on nicotine 
withdrawal as this often compounds the withdrawal of other substances.  
 
Tobacco use during pregnancy is a well-known risk factor for low birth weight and intrauterine 
growth restriction.3 Cornelius and Day reported that in utero tobacco exposure is associated with 
a greater need for handling, poor self-regulation, irritability, and hypertonia.20 Tobacco use 
during pregnancy has been correlated to altered maternal-fetal attachment which can lead to 
many negative short and long-term outcomes.4  
 
In our experience with opioid/nicotine withdrawal in neonates, we observe low birth weight and 
many neonates that are small for gestational age.  While a unique symptomology is not created 
with opioid/nicotine use, nicotine exacerbates the symptoms of opioid withdrawal necessitating 
the use of clonidine in addition to the traditional weaning process with an acceptable opioid 
alternative. Nicotine is so widely used in our population and in many others with substance abuse 
that it has almost become a normality. A neonate with NAS that has no in utero exposure to 
nicotine is a novelty. However, it is important to emphasize the exacerbating effect of nicotine 
leading to a more severe withdrawal profile and note that additional pharmacological 
intervention may be needed to control the withdrawal symptoms. Many women substitute 
smoking for other substances during pregnancy and therefore smoking cessation may not be 
possible or maintainable for many. It is therefore important to know the implications and prepare 
for neonatal treatment.  
 
In addition to nicotine, caffeine use, sometimes in excess, is common during pregnancy. In a 
case documented by Montes Bentura et al21 it is described that excessive caffeine consumption 
during pregnancy can induce neonatal abstinence syndrome in the absence of opioids or other 
drugs. Symptoms of irritability, jitteriness, and vomiting have been reported and while these may 
be extreme cases, they endorse that caffeine consumption can induce withdrawal symptoms in 
neonates much like in adults. This should be considered during treatment of NAS, as caffeine is 




In utero opioid exposure has become a significant problem in neonatal units as the prevalence is 
alarming and still growing. Although treatment of the opioid-induced withdrawal symptoms in 
the neonates is now well established in most hospitals throughout the United States, treating 
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these patients is becoming continually more complex with a disturbing upswing in co-occurring 
abuse. Opioids are just the beginning as exposure to a single substance is a novelty in many 
hospitals. Polysubstance exposure is the reality and it is difficult to understand this population by 
studying one substance at a time. While it is important to note that not all substances will induce 
withdrawal symptoms alone, co-exposure with opioids can cause differing short and long-term 
outcomes and alter severity of withdrawal. This phenomenon causes considerable complications 
for the health care team providing treatment for these neonates. Due to the fast-evolving 
combinations of drug use and the lack of literature, physicians are reliant on treatment 
recommendations that lack references to data supporting the clinical approaches of the 
institution. Physicians are reliant on clinical presentation, the limited power of biological 
samples, the limited literature available, and self-report to base the treatment decisions.  
 
Concerning the pharmacologic therapy, uncertainty exists about the best drug and posology to be 
used to treat NAS.22 When polysubstance abuse is evident, the pharmacologic therapy becomes 
much more difficult due to a combination of the uncertainty that already exists alongside the 
complicated symptom presentation and severity that is accompanied by polysubstance abuse. 
The rationale to use pharmacologic treatment is to ensure proper feeding and development, and 
to foster the maternal infant bond.1 The ideal specific drug used for treatment would safely 
achieve these therapeutic goals while minimizing the total duration of therapy and length of 
hospitalization.1 At our institution, the physicians are faced with complicated exposures leading 
to a severe and oftentimes unique withdrawal profile that renders neonates inconsolable, unable 
to feed, unable to gain weight, and in an overall deteriorating condition. With the lack of 
polysubstance research, our institution has incorporated a stepwise weaning protocol that often 
times includes the use of adjunctive medications such as clonidine, phenobarbital, (Table 3) and 
sometimes includes substances of exposure such as gabapentin to manage severe withdrawal 
symptoms.  These treatment decisions are not made lightly due to the lack of supporting data and 
are decided as a last resort when all other treatment options have failed.  
 
Table 3. Pharmacological treatment of NAS 
 
Drug Clinical Use Mechanism of Action 
Buprenorphine 
Amelioration of withdrawal to 
opioids 
Partial mu agonist, ORL-1 agonist, 
kappa antagonist, delta antagonist 
Clonidine 
Amelioration of autonomic 
hyperactivity 
Alpha-2 adrenergic receptor agonist  
Methadone 
Amelioration of withdrawal to 
opioids 
Synthetic complete mu agonist, N-
methyl-D aspartate antagonist 
Morphine 
Amelioration of withdrawal to 
opioids 
Mu opioid receptor agonist  
Phenobarbital 
Amelioration of hyperactivity, 
promotes disposition and excretion 
of opioids 
GABAA receptor agonist  
Lorazepam 
Amelioration of central nervous 
system disturbances 
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As our communities put more emphasis on improving behavioral health and developing more 
community oriented overall approaches to substance use disorder, the consequences to the 
youngest patients in this epidemic continue to grow. Research models continue to be targeted at a 
single specific substance while the representative in utero exposed neonate is feeling the effect of 
multiple substances. Comprehensive analyses that includes dosage, gestational timing of 
exposure, frequency of exposure and pattern of exposure is extremely difficult to obtain in a 
substance using population when more than one substance is involved.23 Despite these 
difficulties, research and treatment of NAS must consider multiple substances. When it comes to 
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